CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+18.02%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
+$1.06B
(-1.1%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-14.08%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
263
Reduced
171
Closed
24
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$6.59M |
| 2 |
iShares Gold Trust Micro
IAUM
|
$4.62M |
| 3 |
Intuit
INTU
|
$3.73M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.6M |
| 5 |
T-Mobile US
TMUS
|
$2.35M |
Top Sells
| 1 |
Apple
AAPL
|
$17.4M |
| 2 |
NVIDIA
NVDA
|
$12.2M |
| 3 |
Microsoft
MSFT
|
$11.5M |
| 4 |
Amazon
AMZN
|
$8.86M |
| 5 |
Broadcom
AVGO
|
$8.43M |
Sector Composition
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
251
Vericel Corp
VCEL
$1.75B
| $430K | 0.04% |
10,111
+88
| +0.9% | +$3.74K |
|
252
Veracyte
VCYT
$2.39B
| $425K | 0.04% |
15,729
+95
| +0.6% | +$2.57K |
|
253
Diageo
DEO
$61.5B
| $415K | 0.04% |
4,117
| – | – |
|
254
NewAmsterdam Pharma
NAMS
$2.71B
| $408K | 0.04% |
22,549
+521
| +2% | +$9.44K |
|
255
Denali Therapeutics
DNLI
$2.23B
| $408K | 0.04% |
29,178
+50
| +0.2% | +$699 |
|
256
Zai Lab
ZLAB
$3.68B
| $407K | 0.04% |
11,627
-917
| -7% | -$32.1K |
|
257
Recursion Pharmaceuticals
RXRX
$2.03B
| $406K | 0.04% |
80,269
+1,024
| +1% | +$5.18K |
|
258
Deckers Outdoor
DECK
$18.2B
| $403K | 0.04% |
3,908
| – | – |
|
259
NovoCure
NVCR
$1.38B
| $399K | 0.04% |
22,391
+344
| +2% | +$6.12K |
|
260
CG Oncology
CGON
$2.09B
| $398K | 0.04% |
15,310
+40
| +0.3% | +$1.04K |
|
|
GRAL
261
GRAIL, Inc. Common Stock
GRAL
$1.14B
| $397K | 0.04% |
7,725
+985
| +15% | +$50.6K |
|
262
Agios Pharmaceuticals
AGIO
$2.28B
| $387K | 0.04% |
11,632
+139
| +1% | +$4.62K |
|
263
Genmab
GMAB
$15.9B
| $381K | 0.04% |
18,421
-27,781
| -60% | -$574K |
|
264
BioCryst Pharmaceuticals
BCRX
$1.74B
| $377K | 0.04% |
42,027
+113
| +0.3% | +$1.01K |
|
265
AutoZone
AZO
$70.2B
| $371K | 0.03% |
100
| – | – |
|
266
IDEAYA Biosciences
IDYA
$2.23B
| $370K | 0.03% |
17,590
+32
| +0.2% | +$673 |
|
267
Indivior
INDV
$3.07B
| $369K | 0.03% |
25,059
+159
| +0.6% | +$2.34K |
|
268
Disc Medicine
IRON
$2.07B
| $368K | 0.03% |
6,956
+22
| +0.3% | +$1.17K |
|
269
Harmony Biosciences
HRMY
$2.13B
| $364K | 0.03% |
11,533
+30
| +0.3% | +$948 |
|
270
Adaptive Biotechnologies
ADPT
$2.01B
| $355K | 0.03% |
30,512
+910
| +3% | +$10.6K |
|
271
Amicus Therapeutics
FOLD
$2.43B
| $354K | 0.03% |
61,847
+220
| +0.4% | +$1.26K |
|
272
Huazhu Hotels Group
HTHT
$11.3B
| $346K | 0.03% |
10,200
| – | – |
|
273
ARS Pharmaceuticals
SPRY
$1.1B
| $344K | 0.03% |
19,726
+232
| +1% | +$4.05K |
|
274
Beam Therapeutics
BEAM
$1.65B
| $344K | 0.03% |
20,197
+3,175
| +19% | +$54K |
|
275
Tarsus Pharmaceuticals
TARS
$2.47B
| $342K | 0.03% |
8,438
+740
| +10% | +$30K |
|